CN Patent

CN113750091A — 用于治疗癌症的方法

Assigned to Radius Pharmaceuticals Inc · Expires 2021-12-07 · 4y expired

What this patent protects

本文公开了用于治疗癌症的方法，通过向受试者施用治疗有效量的RAD1901或其溶剂化物(例如水合物)或其盐和一种或多种第二治疗剂(例如依维莫司)的组合对抗晚期癌症和/或对既往治疗具有耐药性的癌症来提供额外的益处。所述癌症是雌激素依赖性癌症，例如乳腺癌、卵巢癌、结肠癌、子宫内膜癌、或前列腺癌。

USPTO Abstract

本文公开了用于治疗癌症的方法，通过向受试者施用治疗有效量的RAD1901或其溶剂化物(例如水合物)或其盐和一种或多种第二治疗剂(例如依维莫司)的组合对抗晚期癌症和/或对既往治疗具有耐药性的癌症来提供额外的益处。所述癌症是雌激素依赖性癌症，例如乳腺癌、卵巢癌、结肠癌、子宫内膜癌、或前列腺癌。

Drugs covered by this patent

elacestrant-hydrochloride (ELACESTRANT HYDROCHLORIDE)

Patent Metadata

Patent number: CN113750091A
Jurisdiction: CN
Classification: —
Expires: 2021-12-07
Drug substance claim: No
Drug product claim: No
Assignee: Radius Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.